Developing novel therapies and vaccines to prevent and treat central nervous system disorders.
2025 · 1st Quarter (Jan 1 - Mar 31)
TONIX PHARMACEUTICALS
Filed by FOLEY HOAG LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- FOLEY HOAG LLP
- Client
- TONIX PHARMACEUTICALS
- Filing UUID
- e8f381b6-62d9-4319-ba90-0a5d36eed620
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.